Speaker: Diana E. Lake, MD, Memorial Sloan Kettering Cancer Center. Dr. Lake is a medical oncologist with a practice that is devoted solely to the care of breast cancer patients. Dr. Lake’s research interests involve all areas of breast cancer but focus mainly on the development of new therapies, prevention of cancer recurrence following surgery, and treatment of recurrent disease.
Working in conjunction with her colleagues on the Breast Cancer Medicine Service at MSKCC and as the liaison in breast medicine to Alliance for Clinical Trials in Oncology (a national clinical trials cooperative research group sponsored by the National Cancer Institute), she is involved in clinical trials to develop better hormonal therapies and improved approaches to treatment before surgery.
Dr. Lake is a past member of the National Institutes of Health (NIH) Scientific Review Committee, and has previously served on the NIH Cooperative Group Review and its Cancer Education committees and has received the Memorial Sloan-Kettering Cancer Center fellowship. She is a member of the NYS Health Research Science Board.
Hormonal therapies are commonly used to treat breast cancer that is estrogen-receptor positive. Examples: Tamoxifen (Nolvadex), Arimidex (Anastrazole), Aromasin (Exemestane), Femara (Letrozole), etc. Hormonal therapy may be used at different points in a treatment plan and to treat various stages of breast cancer.
- What are the different hormonal therapy options?
- What is the latest research?
- How have recommendations changed?
- Should I continue treatment for 5 years? 10 years? forever?
- Question & answer period.
Audio and slides from Support Connection’s Webinar “Hormonal Therapies for Breast Cancer.” – Recorded on Oct. 23, 2018